TAGRISSO, generically known as osimertinib, is a highly effective oral medication primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which specifically target the epidermal growth factor receptor (EGFR) T790M mutation, a common mutation in NSCLC patients. TAGRISSO works by blocking the activity of the EGFR mutation, thereby inhibiting the growth and spread of cancer cells. It is often prescribed for patients who have progressed on or after EGFR TKI therapy. Due to its targeted approach, TAGRISSO has become a pivotal treatment option, offering hope for improved outcomes in the management of advanced NSCLC with EGFR mutations.